Hematology Analyzers and Reagents Market Report 2025

This Hematology Analyzers and Reagents market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The hematology analyzers and reagents market size has grown strongly in recent years. It will grow from $4.9 billion in 2024 to $5.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, aging population, increased disease burden, and rising prevalence of infectious diseases.

The hematology analyzers and reagents market size is expected to see strong growth in the next few years. It will grow to $6.63 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to global health concerns, growing investment in hematology analyzer and reagent infrastructure, personalized medicine, expansion of remote monitoring. Major trends in the forecast period include advancements in technology, high-sensitivity testing, molecular hematology testing, automation and integration, point-of-care testing (POCT), data analytics and artificial intelligence, and digital hematology.

The increasing occurrence of infectious diseases is projected to fuel the growth of the hematology analyzers and reagents market in the future. Infectious diseases are illnesses caused by pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites, which can be transmitted from person to person or from environmental sources. The rise in infectious diseases is influenced by several interconnected factors, including globalization, which allows for the swift spread of pathogens, antimicrobial resistance stemming from excessive antibiotic use, and varying socioeconomic conditions. Data generated from hematology analyzers support epidemiological research by enabling public health officials to monitor outbreaks and understand the transmission dynamics of infectious diseases. For example, in March 2024, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, indicating a rise of 1,295 cases. Therefore, the growing incidence of infectious diseases is driving the advancement of the hematology analyzers and reagents market.

The increasing prevalence of blood disorders is anticipated to drive the growth of the hematology analyzers and reagents market in the future. Blood disorders refer to medical conditions that disrupt the normal function of blood components, such as red blood cells, white blood cells, or platelets. Hematology analyzers and reagents are essential tools for diagnosing and monitoring these disorders, including cancers, by evaluating blood cell counts and morphology. For example, in July 2024, Cancer Research UK, a charity based in the UK, projected that the average number of new Hodgkin lymphoma cases per year in the UK would rise from approximately 2,400 cases during 2023-2025 to around 2,900 cases by 2038-2040. Consequently, the growing prevalence of blood disorders is driving the advancement of the hematology analyzers and reagents market.

Manufacturers in the hematology analyzers sector are increasingly directing investments into the development of analyzers integrated with microfluidics technology, enabling reduced sample and reagent volumes. Microfluidics technology, handling liquid flow within micrometer-sized channels, substantially cuts down reagent consumption in these analyzers, thus lowering operational costs. Notable examples include BioSystems' HA5 hematology system utilizing microfluidics, using approximately 75% fewer reagents than standard analyzers, and DiaSys' respons®3H and respons®5H systems, also employing microfluidics and consuming 70% fewer reagents, showcasing the industry's shift towards cost-efficient technologies.

Major players in the hematology analyzers and reagents market are strategically focusing on compact, integrated analyzer development to gain a competitive edge. These systems, offering efficient blood cell analysis in a space-saving format, streamline diagnostic processes. Mindray Bio-Medical Electronics Co. Ltd.'s March 2022 launch of the BC-700 Series, an integrated CBC and ESR hematology analyzer tailored for small-to-mid-sized labs, exemplifies this trend. This compact system merges CBC and ESR analysis, delivering rapid and accurate results within 1.5 minutes, significantly reducing turnaround time compared to traditional ESR tests, catering to the efficiency needs of smaller labs.

In January 2024, Fujirebio Holdings, a diagnostics company based in Japan, entered into a partnership with Agappe Diagnostics Ltd. This collaboration aims to work together on the development of advanced diagnostic technologies and to broaden their product offerings in the global healthcare market. Agappe Diagnostics Ltd., located in India, specializes in creating and manufacturing a diverse array of innovative diagnostic solutions.

Hematology analyzers play a crucial role in providing comprehensive blood analysis, including a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. They possess the capability to detect minute cell populations, aiding in the diagnosis of rare blood conditions and assessing cell morphology.

The primary products within the realm of hematology analyzers and reagents include various instruments and associated reagents: hematology analyzers, hemostasis analyzers, plasma protein analyzers, hemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyzers, flow cytometers, slide stainers, differential counters, and hematology stains. Hematology analyzers specifically measure hemoglobin concentration in blood samples. These analyzers find applications in various medical conditions such as anemias, blood cancers, hemorrhagic disorders, infections, immune-related conditions, and others. They are utilized by end-users including specialized research institutes, hospitals, specialized diagnostic centers, and other healthcare facilities for a wide range of diagnostic purposes.

The hematology analyzers and reagents market research report is one of a series of new reports that provides hematology analyzers and reagents market statistics, including hematology analyzers and reagents industry global market size, regional shares, competitors with a hematology analyzers and reagents market share, detailed hematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the hematology analyzers and reagents industry. This hematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the hematology analyzers and reagents market include Abbott Laboratories, Bio-Rad Laboratories, Horiba Ltd., Siemens AG, Sysmex Corporation, BioSystems Diagnostics Pvt. Ltd, Boule Diagnostics, Danaher Corporation, Diatron MI PLC, Drew Scientific, EKF Diagnostics, Mindray, Nihon Kohden, Ortho Clinical Diagnostics, Roche, Beckman Coulter, Bayer AG, Heska, Drucker, Instrumentation Laboratory, Abaxis Inc., Accriva Diagnostics, ACON, Diamond Diagnostics, ERBA Diagnostics, Hycel, Maccura Biotechnology Co. Ltd., Genrui Biotech Inc., A&T Corporation, Beijing Succeeder Technology Inc., Diagnostica Stago SAS.

North America was the largest region in the hematology analyzers and reagents market in 2024. Western Europe was the second-largest region in the hematology analyzers and reagents market report. The regions covered in the hematology analyzers and reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hematology analyzers and reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The hematology analyzers and reagents market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimetry. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.